Yosuf, Nadia

Email: nyosuf@fredhutch.org
Fax: No facsimile telecopying (also known as "fax") telephone number is available for this contact
DMCC Person ID: 4863
EDRN Title: Primary Admin Staff
Specialty: None given

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

None Available.

Closed Protocols

No closed protocols.


Publication Name PubMed ID Journal
17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. 32130059 J Clin Oncol
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. 18550118 J. Urol.
A <i>K</i>-fold Averaging Cross-validation Procedure. 27630515 J Nonparametr Stat
A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers. 28482112 Biometrics
A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. 12925511 Biostatistics
A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. 31376183 Prostate
A Gastric Glycoform of MUC5AC Is a Biomarker of Mucinous Cysts of the Pancreas. 27992432 PLoS One
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. 23232570 Adv Anat Pathol
A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. 19435894 Cancer Res.
A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. 18056174 Clin. Cancer Res.
A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. 18316555 Clin. Cancer Res.
A new family-based association test via a least-squares method. 16451567 BMC Genet.
A parametric ROC model-based approach for evaluating the predictiveness of continuous markers in case-control studies. 19459841 Biometrics
A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. 28376184 J Natl Cancer Inst
A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. 30137376 J. Natl. Cancer Inst.
A practical multifaceted approach to selecting differentially expressed genes. 19455259 Cancer Inform
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. 20447916 Cancer Epidemiol. Biomarkers Prev.
A regularized multivariate regression approach for eQTL analysis. 26085849 Stat Biosci
A sparse Ising model with covariates. 25099186 Biometrics
A statistical method for detecting differentially expressed SNVs based on next-generation RNA-seq data. 27276420 Biometrics
A two-stage approach for dynamic prediction of time-to-event distributions. 26748812 Stat Med
A web-based system for managing and co-ordinating multiple multisite studies. 16279578 Clin Trials
Accommodating Covariates in ROC Analysis. 20046933 Stata J
Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. 19322904 Int. J. Cancer
Adding Rigor to Biomarker Evaluations-EDRN Experience. 33172885 Cancer Epidemiol Biomarkers Prev
Addressing patient heterogeneity in disease predictive model development. 34184256 Biometrics
Addressing patient heterogeneity in disease predictive model development. 34184256 Biometrics
Adjusting for covariate effects on classification accuracy using the covariate-adjusted receiver operating characteristic curve. 22822245 Biometrika
Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting. 18477651 Am. J. Epidemiol.
Adopting nested case-control quota sampling designs for the evaluation of risk markers. 23807695 Lifetime Data Anal
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. 19362088 Gastroenterology
An Automated Peak Identification/Calibration Procedure for High-Dimensional Protein Measures From Mass Spectrometers. 14615632 J. Biomed. Biotechnol.
Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. 24807840 J. Proteome Res.
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. 17981926 Clin. Chem.
Analyzing LC-MS/MS data by spectral count and ion abundance: two case studies. 24163717 Stat Interface
Application of a methylation gene panel by quantitative PCR for lung cancers. 16644104 Cancer Lett.
Application of Multidimensional Selective Item Response Regression Model for Studying Multiple Gene Methylation in SV40 Oncogenic Pathways. 19830254 J Am Stat Assoc
Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers. 16542256 Biometrics
Aspects of the design and analysis of high-dimensional SNP studies for disease risk estimation. 16443924 Biostatistics
Assessing accuracy of mammography in the presence of verification bias and intrareader correlation. 15737102 Biometrics
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. 16622122 J. Natl. Cancer Inst.
Assessing risk prediction models in case-control studies using semiparametric and nonparametric methods. 20527013 Stat Med
Assessing the diagnostic accuracy of a sequence of tests. 12925502 Biostatistics
Assessing the incremental value of new biomarkers based on OR rules. 30590454 Biostatistics
Assessing the value of risk predictions by using risk stratification tables. 19017593 Ann. Intern. Med.
Assessing treatment-selection markers using a potential outcomes framework. 22299708 Biometrics
Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. 30003238 JAMA Oncol
Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. 28520829 JAMA Oncol
Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study. 14504198 Cancer Epidemiol. Biomarkers Prev.
Association of serum phospholipid fatty acids with breast cancer risk among postmenopausal cigarette smokers. 19255861 Cancer Causes Control
Asymptotic Properties of the Sequential Empirical ROC, PPV and NPV Curves Under Case-Control Sampling. 24039313 Ann Stat
Bayesian inference of hub nodes across multiple networks. 30051914 Biometrics
Bias-reduced estimators and confidence intervals for odds ratios in genome-wide association studies. 18310059 Biostatistics
Bias-reduced estimators and confidence intervals for odds ratios in genome-wide association studies. 18310059 Biostatistics
Bias-reduced estimators and confidence intervals for odds ratios in genome-wide association studies. 18310059 Biostatistics
Biases introduced by choosing controls to match risk factors of cases in biomarker research. 22730452 Clin. Chem.
Biomarker evaluation and comparison using the controls as a reference population. 18755739 Biostatistics
Biomarker-based methods for determining noncompliance in a prevention trial. 12505245 Control Clin Trials
Biomarker-based methods for determining noncompliance in a prevention trial. 12505245 Control Clin Trials
Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN. 32532830 Cancer Epidemiol Biomarkers Prev
Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment. 34995129 J Clin Oncol
Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. 12324514 Clin. Chem.
Boosting with missing predictors. 19948743 Biostatistics
Borrowing Information across Populations in Estimating Positive and Negative Predictive Values. 22021938 J R Stat Soc Ser C Appl Stat
Can urinary PCA3 supplement PSA in the early detection of prostate cancer? 25385735 J. Clin. Oncol.
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. 19758683 Urology
Cancer Biomarkers and Big Data: A Planetary Science Approach. 32976775 Cancer Cell
Cancer Biomarkers and Big Data: A Planetary Science Approach. 32976775 Cancer Cell
Characterizing expected benefits of biomarkers in treatment selection. 25190512 Biostatistics
Characterizing expected benefits of biomarkers in treatment selection. 25190512 Biostatistics
Classification versus association models: should the same methods apply? 20515278 Scand. J. Clin. Lab. Invest. Suppl.
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. 15741570 J. Natl. Cancer Inst.
Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. 19058137 Prostate
Combining biomarkers linearly and nonlinearly for classification using the area under the ROC curve. 27058981 Stat Med
Combining biomarkers to detect disease with application to prostate cancer. 14557109 Biostatistics
Combining multiple biomarkers linearly to maximize the partial area under the ROC curve. 29082535 Stat Med
Combining predictors for classification using the area under the receiver operating characteristic curve. 16542249 Biometrics
Combining results of microarray experiments: a rank aggregation approach. 17049026 Stat Appl Genet Mol Biol
Combining several screening tests: optimality of the risk score. 12230001 Biometrics
Commentary: Reporting standards are needed for evaluations of risk reclassification. 21571811 Int J Epidemiol
Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929). 17671958 Stat Med
Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs. 16895044 Clin Trials
Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs. 16895044 Clin Trials
Comparison of two correlated ROC surfaces at a given pair of true classification rates. 30010205 Stat Med
Comparison of two correlated ROC curves at a given specificity or sensitivity level. 27324068 Stat Med
Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futility. 22238117 Stat Med
Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility. 19097251 Stat Med
Constructing dynamic treatment regimes with shared parameters for censored data. 31951041 Stat Med
Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. 25471344 Cancer Epidemiol. Biomarkers Prev.
Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. 30076904 J Urol
Contrasting two frameworks for ROC analysis of ordinal ratings. 20147599 Med Decis Making
Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules. 33137463 J Thorac Oncol
Copy number alterations are associated with metastatic-lethal progression in prostate cancer. 32071439 Prostate Cancer Prostatic Dis
Cruciferous vegetable supplementation in a controlled diet study alters the serum peptidome in a GSTM1-genotype dependent manner. 21272319 Nutr J
Data reduction using a discrete wavelet transform in discriminant analysis of very high dimensionality data. 12762451 Biometrics
Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. 26431551 PLoS One
Design and estimation for evaluating principal surrogate markers in vaccine trials. 23409839 Biometrics
Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. 30699099 Am J Gastroenterol
Detecting genomic aberrations using products in a multiscale analysis. 19817738 Biometrics
Development of common data elements: the experience of and recommendations from the early detection research network. 12706181 Int J Med Inform
Diagnostic markers for early detection of ovarian cancer. 18258665 Clin. Cancer Res.
Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. 15580314 Oncogene
Distribution-free ROC analysis using binary regression techniques. 12933607 Biostatistics
DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs. 32226005 PLoS Genet
DNA methylation profiles in African American prostate cancer patients in relation to disease progression. 26902887 Genomics
Does the net reclassification improvement help us evaluate models and markers? 24592500 Ann. Intern. Med.
Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma. 34954100 Contemp Clin Trials
Efficient use of longitudinal CD4 counts and viral load measures in survival analysis. 22415871 Stat Med
Epidemiologic methods developments: a look forward to the year 2032. 17855116 Ann Epidemiol
Epidemiology informing clinical practice: from bills of mortality to population laboratories. 16341118 Nat Clin Pract Oncol
Estimating improvement in prediction with matched case-control designs. 23358916 Lifetime Data Anal
Estimating Risk with Time-to-Event Data: An Application to the Women's Health Initiative. 25018574 J Am Stat Assoc
Estimating the capacity for improvement in risk prediction with a marker. 18714084 Biostatistics
Estimating the diagnostic likelihood ratio of a continuous marker. 20639522 Biostatistics
Estimating the receiver operating characteristic curve in studies that match controls to cases on covariates. 23601953 Acad Radiol
Estimation and Comparison of Receiver Operating Characteristic Curves. 20161343 Stata J
Evaluating a New Cancer Screening Blood Test: Unintended Consequences and the Need for Clarity in Policy Making. 32761203 J Natl Cancer Inst
Evaluating and comparing biomarkers with respect to the area under the receiver operating characteristics curve in two-phase case-control studies. 26883772 Biostatistics
Evaluating classification performance of biomarkers in two-phase case-control studies. 30209824 Stat Med
Evaluating incremental values from new predictors with net reclassification improvement in survival analysis. 23254468 Lifetime Data Anal
Evaluating longitudinal markers under two-phase study designs. 29912281 Biostatistics
Evaluating markers for selecting a patient's treatment. 15606407 Biometrics
Evaluating prognostic accuracy of biomarkers in nested case-control studies. 21856652 Biostatistics
Evaluating prognostic accuracy of biomarkers under competing risk. 22150576 Biometrics
Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. 29301497 BMC Med Res Methodol
Evaluating technologies for classification and prediction in medicine. 16320261 Stat Med
Evaluating the predictive value of biomarkers with stratified case-cohort design. 23173848 Biometrics
Evaluating the predictiveness of a continuous marker. 17489968 Biometrics
Evaluating the ROC performance of markers for future events. 18064569 Lifetime Data Anal
Evaluation of matrix-assisted laser desorption/ionization-time of flight mass spectrometry proteomic profiling: identification of alpha 2-HS glycoprotein B-chain as a biomarker of diet. 15841498 Proteomics
Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. 15613711 Clin. Chem.
Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. 30651550 Nat Commun
Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model. 12807723 Carcinogenesis
Factors influencing serum CA125II levels in healthy postmenopausal women. 11352859 Cancer Epidemiol. Biomarkers Prev.
FDR-controlling testing procedures and sample size determination for microarrays. 15977294 Stat Med
Further insight into the incremental value of new markers: the interpretation of performance measures and the importance of clinical context. 22875756 Am. J. Epidemiol.
GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. 30464023 Cancer Epidemiol. Biomarkers Prev.
Gauging the performance of SNPs, biomarkers, and clinical factors for predicting risk of breast cancer. 18612128 J. Natl. Cancer Inst.
Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China. 19064562 Cancer Epidemiol. Biomarkers Prev.
Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas. 20800559 Mol Oncol
Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women. 17624589 Breast Cancer Res. Treat.
Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A. 25733690 Mol Cell Proteomics
Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9. 26998508 Cell Mol Gastroenterol Hepatol
Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. 20395854 Ann. Surg.
Group sequential testing of the predictive accuracy of a continuous biomarker with unknown prevalence. 26537180 Stat Med
Hybrid design evaluating new biomarkers when there is an existing screening test. 33540472 Stat Med
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. 21953299 Hepatology
Identification of the optimal treatment regimen in the presence of missing covariates. 31774192 Stat Med
Identifying optimal biomarker combinations for treatment selection through randomized controlled trials. 25948620 Clin Trials
Identifying optimal biomarker combinations for treatment selection via a robust kernel method. 25124089 Biometrics
Identifying target populations for screening or not screening using logic regression. 15568185 Stat Med
Immunohistochemical validation of expression microarray results. 15858137 J Mol Diagn
Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. 26260109 Clin. Gastroenterol. Hepatol.
Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. 28258053 Cancer Epidemiol Biomarkers Prev
Improving biomarker identification with better designs and reporting. 21666069 Clin. Chem.
Improving risk classification of critical illness with biomarkers: a simulation study. 23566734 J Crit Care
Improving the quality of biomarker discovery research: the right samples and enough of them. 25837819 Cancer Epidemiol. Biomarkers Prev.
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. 15824739 Oncogene
Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. 29422418 Eur Urol Focus
Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. 22277732 Cancer Prev Res (Phila)
Insights into latent class analysis of diagnostic test performance. 17085745 Biostatistics
Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and the risk of fibrocystic breast conditions among Chinese women. 16331609 Int. J. Cancer
Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. 21653254 Mol. Cell Proteomics
Integrating the predictiveness of a marker with its performance as a classifier. 17982157 Am. J. Epidemiol.
Joint modeling, covariate adjustment, and interaction: contrasting notions in risk prediction models and risk prediction performance. 21968770 Epidemiology
Learning-based biomarker-assisted rules for optimized clinical benefit under a risk constraint. 31833561 Biometrics
Letter by Pepe et al regarding article, "Use and misuse of the receiver operating characteristic curve in risk prediction". 17679623 Circulation
Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. 15105181 Am. J. Epidemiol.
Low Prevalence of Screen-Detected Colorectal Cancer in an Average-Risk Population: The New Normal. 34547437 Clin Gastroenterol Hepatol
Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability. 22412972 PLoS ONE
MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas. 26342024 Cancer Prev Res (Phila)
Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value. 17501939 Biometrics
Measures to summarize and compare the predictive capacity of markers. 20224632 Int J Biostat
Measuring the performance of markers for guiding treatment decisions. 21320940 Ann. Intern. Med.
Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test. 20054437 Stat Biopharm Res
Model checking for ROC regression analysis. 17447940 Biometrics
Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. 29775599 Gastroenterology
Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. 18483343 Cancer Epidemiol. Biomarkers Prev.
Net risk reclassification p values: valid or misleading? 24681599 J. Natl. Cancer Inst.
New connections between old pathways: PDK1 signaling promotes cellular transformation through PLK1-dependent MYC stabilization. 24124229 Cancer Discov
Nidogen-2: a new serum biomarker for ovarian cancer. 19883638 Clin. Biochem.
Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs. 30555194 J Am Stat Assoc
Observational studies, clinical trials, and the women's health initiative. 17943443 Lifetime Data Anal
Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. 18794547 J. Clin. Oncol.
On longitudinal prediction with time-to-event outcome: Comparison of modeling options. 27438160 Biometrics
Optimized normalization for antibody microarrays and application to serum-protein profiling. 15793073 Mol. Cell Proteomics
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. 26327354 J Urol
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. 21372036 Cancer Prev Res (Phila)
Partial AUC estimation and regression. 14601762 Biometrics
Partially supervised learning using an EM-boosting algorithm. 15032790 Biometrics
Partly conditional survival models for longitudinal data. 16011684 Biometrics
Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. 18948370 Clin. Chem.
Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). 30664734 Prostate Cancer Prostatic Dis.
Personalized Evaluation of Biomarker Value: A Cost-Benefit Perspective. 27446505 Stat Biosci
Personalized Integrated Network Modeling of the Cancer Proteome Atlas. 30297783 Sci Rep
Phases of biomarker development for early detection of cancer. 11459866 J. Natl. Cancer Inst.
Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. 18840817 J. Natl. Cancer Inst.
Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. 26549697 Sci Rep
Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer. 33893071 Cancer Prev Res (Phila)
Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer. 33893071 Cancer Prev Res (Phila)
Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women. 18483327 Cancer Epidemiol. Biomarkers Prev.
Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis. 16921513 Prostate
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. 17455987 PLoS Med.
Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. 12483774 Stat Med
Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. 12483774 Stat Med
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. 18766180 Br. J. Cancer
Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score. 20875091 BJU Int.
Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score. 20875091 BJU Int.
Presence of simian virus 40 DNA sequences in human lymphomas. 11897287 Lancet
Prevalidation of salivary biomarkers for oral cancer detection. 22301830 Cancer Epidemiol. Biomarkers Prev.
Pro-surfactant protein B as a biomarker for lung cancer prediction. 24248694 J. Clin. Oncol.
Problems with risk reclassification methods for evaluating prediction models. 21555714 Am. J. Epidemiol.
Prospective accuracy for longitudinal markers. 17688486 Biometrics
Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. 19836772 J. Urol.
Quantifying and comparing the predictive accuracy of continuous prognostic factors for binary outcomes. 14744831 Biostatistics
Quantifying and comparing the accuracy of binary biomarkers when predicting a failure time outcome. 15122736 Stat Med
Quantifying peptide signal in MALDI-TOF mass spectrometry data. 16195224 Mol. Cell Proteomics
Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network. 30439517 Contemp Clin Trials
Re: "Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study". 23524037 Am. J. Epidemiol.
Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. 30099328 Cancer Epidemiol
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. 29433975 Eur. Urol.
Reproducible two-dimensional capillary electrophoresis analysis of Barrett's esophagus tissues. 16944874 Anal. Chem.
Resampling Procedures for Making Inference under Nested Case-control Studies. 24436503 J Am Stat Assoc
Response. 25432412 J. Natl. Cancer Inst.
Robust prediction of t-year survival with data from multiple studies. 20670303 Biometrics
Robust risk prediction with biomarkers under two-phase stratified cohort design. 27037494 Biometrics
Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. 29433973 Eur Urol
Sample size calculations for comparative studies of medical tests for detecting presence of disease. 11870820 Stat Med
Scale-based normalization of spectral data. 17192066 Cancer Biomark
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. 18024530 Clin. Chem.
Selecting Biomarkers for building optimal treatment selection rules using Kernel Machines. 32921837 J R Stat Soc Ser C Appl Stat
Selecting differentially expressed genes from microarray experiments. 12762450 Biometrics
Semiparametric estimation of time-dependent ROC curves for longitudinal marker data. 15475423 Biostatistics
Semiparametric isotonic regression analysis for risk assessment under nested case-control and case-cohort designs. 31868119 Stat Methods Med Res
Semiparametric methods for evaluating the covariate-specific predictiveness of continuous markers in matched case-control studies. 21562626 J R Stat Soc Ser C Appl Stat
Semiparametric methods for evaluating risk prediction markers in case-control studies. 22822247 Biometrika
Semiparametric models of time-dependent predictive values of prognostic biomarkers. 19397579 Biometrics
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. 28376157 J Natl Cancer Inst
Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer. 26813970 Cancer Prev Res (Phila)
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. 12097261 Cancer Res.
Signal detection in high-resolution mass spectrometry data. 18173224 J. Proteome Res.
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. 12455028 Int. J. Cancer
Standardizing diagnostic markers to evaluate and compare their performance. 16135934 Epidemiology
Statistical Aspects of the Use of Biomarkers in Nutritional Epidemiology Research. 19841649 Stat Biosci
Statistical considerations in combining biomarkers for disease classification. 15322313 Dis. Markers
Statistical inference for net benefit measures in biomarker validation studies. 31732971 Biometrics
Statistical issues in the evaluation of screening and early detection modalities. 18452826 Urol. Oncol.
Statistical Methods for Tissue Array Images - Algorithmic Scoring and Co-training. 22984376 Ann Appl Stat
Strategies for validating biomarkers using data from a reference set. 31420985 Biostatistics
Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration. 21414753 J Clin Epidemiol
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. 21434890 Eur. J. Clin. Invest.
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. 21424820 Eur. J. Epidemiol.
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. 21407270 Eur. J. Hum. Genet.
Structured penalties for functional linear models-partially empirical eigenvectors for regression. 22639702 Electron J Stat
Survival model predictive accuracy and ROC curves. 15737082 Biometrics
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. 32852532 JAMA Oncol
Telomere length in the colon declines with age: a relation to colorectal cancer? 16537718 Cancer Epidemiol. Biomarkers Prev.
Testing for improvement in prediction model performance. 23296397 Stat Med
The analysis of placement values for evaluating discriminatory measures. 15180681 Biometrics
The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma. 26712941 Cancer Prev Res (Phila)
The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers. 23193062 Clin. Chem.
The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. 23313212 J. Urol.
The joint graphical lasso for inverse covariance estimation across multiple classes. 24817823 J R Stat Soc Series B Stat Methodol
The length of the receiver operating characteristic curve and the two cutoff Youden index within a robust framework for discovery, evaluation, and cutoff estimation in biomarker studies involving improper receiver operating characteristic curves. 33530129 Stat Med
The optimal ratio of cases to controls for estimating the classification accuracy of a biomarker. 16428259 Biostatistics
The potential of genes and other markers to inform about risk. 20160267 Cancer Epidemiol. Biomarkers Prev.
The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting. 22552047 Urol. Oncol.
The sensitivity and specificity of markers for event times. 16079162 Biostatistics
The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. 19367279 Br. J. Cancer
Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. 18382671 PLoS ONE
Time-dependent Predictive Values of Prognostic Biomarkers with Failure Time Outcome. 19655041 J Am Stat Assoc
Tree-based Ensemble Methods For Individualized Treatment Rules. 31650095 Biostat Epidemiol
Two-stage biomarker panel study and estimation allowing early termination for futility. 25964662 Biostatistics
Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. 18519043 Gastroenterology
Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. 21363920 Cancer Res.
Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients. 32722209 Cancers (Basel)
Ultrasensitive detection and characterization of posttranslational modifications using surface-enhanced Raman spectroscopy. 16737206 Anal. Chem.
Unbiased estimation of biomarker panel performance when combining training and testing data in a group sequential design. 26845527 Biometrics
Updating risk prediction tools: a case study in prostate cancer. 22095849 Biom J
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. 23515404 Clin. Cancer Res.
Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. 33080150 J Urol
Using the ROC curve for gauging treatment effect in clinical trials. 16220481 Stat Med
Validation of a novel model for the early detection of hepatocellular carcinoma. 30675135 Clin Proteomics
Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. 30557738 Clin Gastroenterol Hepatol
Vitamin D receptor gene polymorphisms and prostate cancer risk. 15065089 Prostate
When does combining markers improve classification performance and what are implications for practice? 23348801 Stat Med

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.

Version 5.1.3